Ryboquin acquires gene therapy pioneers Nanogenics

TRICAPITAL investee Ryboquin has been hitting the headlines after its recent acquisition of gene therapy pioneers Nanogenics. The new combined company, Nanogenics Ltd, is set to revolutionise gene therapy by pioneering the safe, efficacious and regular dosing of all forms of gene therapy.

Nanogenics is developing LipTide™, an artificial virus. Currently viruses and liposomes are used, which have limited applications, severe side-effects and expensive technical problems.

Here’s some of the press coverage:

Herald: Selkirk-based biotech firm Ryboquin acquires Nanogenic Solutions to advance gene therapy

BBC: Selkirk-based Ryboquin completes company acquisition

Daily Business Group: Borders drugs firm plans IPO after £4.45m acquisition

Comments are closed.